沐舒坦预防早产儿肺透明膜病  

Ambroxol Prevents Premature Infant Pulmenary Hyaline Membrane Disease

作　　者：章蕾[1] 朱钟治[1] 唐海婷[1] 侍庆[1] 

机构地区：[1]上海第二医科大学瑞金医院妇产科,上海200025

出　　处：《上海医科大学学报》2000年第6期509-510,513,共3页Journal of Fudan University(Medical Science)

摘　　要：目的　探讨在应用肾上腺皮质激素的基础上加用沐舒坦预防早产儿肺透明膜病 (HMD)的效果。方法　设激素 +沐舒坦组 (n =2 8)为观察组 ,单用激素为对照组 (n =35 ) ,观察两组早产儿HMD的发生率 ;观察两组窒息儿中HMD的发生情况及不同胎龄时HMD的发生率。结果　 (1)对照组HMD的发生率为 11.4% ,观察组为 0 % ,两组有显著性差异 (P <0 .0 5 ) ;(2 )对照组中孕周 <32周、33～ 34周及 35～ 36周的早产儿HMD的发生率分别是 2 8.7%、15 .38%和 0 % ,而在观察组中均未发生 ;(3)对照激素组 12例窒息儿中有 3人发生HMD ,观察组 6例窒息儿中无一人发生HMD。结论　在产前应用激素的基础上 。Purpose To evaluate the effects of ambroxol on prevention of premature babies with hyaline membrane disease(HMD) with prenatal corticosteroids. Methods Premature neonates gestational age 26-36 weeks were divided into two groups,receiving:(1) Ambroxol 30 mg/kg through umbilical vein at birth(group A, n =28) and (2) a control group not given ambroxol (group B, n =35).All the babies were exposed prenatally corticosteroids. Results (1) Occurrence rate of HMD in group A was 0%,group B was 11.4 %,there was significant difference ( P <0.05).(2) Mean fetal age of group A was 32.47+/- 4.5 pregnant weeks,group B is 32.86+/-7.1 weeks.No significant difference existed.(3) Different fetal age in gruop B,such as pregnant weeks≤32,33-34,35-36,the HMD rate was separately 28.7%, 15.38 % and 0%,no case was found in group A.(4) There cases of 12 neonatal asphyxia happened in group B,but none of 6 in group A. Conclusions Definite effect can be received by applying ambroxol to prevent premature infant HMD after delivery on the bases of adenotropin before delivery.

关 键 词：肺透明膜病 沐舒坦 早产儿 药物预防 HMD 

分 类 号：R722.606[医药卫生—儿科] R722.120.5[医药卫生—临床医学]